RTP Mobile Logo
Select Publications

Aguilar EJ et al. Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression. Ann Oncol 2019;30(10):1653-9. Abstract

André T et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med 2020;383(23):2207-18. Abstract

Brahmer JR et al. KEYNOTE-024 5-year OS update: First-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS) ≥50%. ESMO 2020;Abstract LBA51.

Garon EB et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015;372(21):2018-28. Abstract

Gopalaskrishnan V et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 2018;359(6371):97-103. Abstract

Hause RJ et al. Classification and characterization of microsatellite instability across 18 cancer types. Nat Med 2016;22(11):1342-50. Abstract

Hellmann MD et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med 2018;378(22):2093-104. Abstract

Herbst RS et al. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. N Engl J Med 2019;383(14):1328-39. Abstract

Luchini C et al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: A systematic review-based approach. Ann Oncol 2019;30(8):1232-43. Abstract

Marabelle A et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: Prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 2020;21(10):1353-65. Abstract

Peters S et al. Tumor mutational burden (TMB) as a biomarker of survival in metastatic non-small cell lung cancer (mNSCLC): Blood and tissue TMB analysis from MYSTIC, a Phase III study of first-line durvalumab ± tremelimumab vs chemotherapy. AACR 2019;Abstract CT074.

Routy B et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 2018;359(6371):91-7. Abstract

Takagi T et al. Heme oxygenase-1 prevents murine intestinal inflammation. J Clin Biochem Nutr 2018;63(3):169-74. Abstract

Tray N et al. Predictive biomarkers for checkpoint immunotherapy: Current status and challenges for clinical application. Cancer Immunol Res 2018;6(10):1122-8. Abstract

Wolchok JD et al. Nivolumab and ipilimumab in advanced melanoma. N Engl J Med 2017;377(25):2503-4. Abstract